GenoMed's Treatment Showing 100% Response Rate Among Immunocompetent Patients; Nationwide Trial Gaining Momentum
Friday April 23, 8:45 am ET
biz.yahoo.com
ST. LOUIS, April 23 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, said today that it will be limiting its treatment for West Nile virus encephalitis to immunocompetent patients only, where it has posted a 100% success rate.
Ten out of ten patients, including 4 over the age of 70, responded completely to GenoMed's treatment. The only failure since late August 2003 when the trial began was a young woman with chronic leukemia treated last September.
So far this April, 31 people have downloaded GenoMed's West Nile virus trial document. These include 4 physicians; 3 public health officers, including one from Manitoba, Canada and one from Arizona; 2 people from blood banks and 2 more from hospitals.
In addition, 6 patients with chronic residual disease after getting West Nile virus encephalitis last summer have signed up for GenoMed's trial. One patient with right leg paralysis who has been on GenoMed's treatment during the winter has recovered nearly complete function of his right leg.
GenoMed's patent-pending protocol uses blood-pressure drugs that are safe and already familiar to most physicians. They're carried in every drug store. The protocol, developed by Dr. David Moskowitz, the Company's Chairman, CEO and Chief Medical Officer, is based on the theory that brain inflammation and death result from an over-response by the patient's immune system to the West Nile virus. GenoMed's protocol gently suppresses the immune system at an early step in its activation. The results of Dr. Moskowitz's first eight patients will be published soon in a peer-reviewed medical journal.
If GenoMed's current 100% cure rate for patients who aren't immunosuppressed holds up, GenoMed hopes to prevent all deaths and cases of paralysis from West Nile virus encephalitis in the general population this season. Immunosuppressed patients include those with AIDS, those taking chemotherapy for cancer, and organ transplant recipients. GenoMed's treatment approach is already known not to work for this group, unfortunately. Two other biotechnology companies offer treatments which may benefit immunosuppressed patients.
For the general population, GenoMed recommends beginning its treatment protocol once a person develops fever and flu-like symptoms after a mosquito bite, and not waiting for encephalitis to develop.
GenoMed hopes to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" button at genomedics.com .
Dr. Moskowitz is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz's research on viruses, including West Nile virus, avian influenza ("bird flu"), and SARS, are regarded as innovative approaches for otherwise incurable diseases.
About GenoMed
GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. This summer the Company is conducting a nationwide free clinical trial for West Nile virus encephalitis which will be published before the 2005 West Nile virus season begins. If the Company's protocol continues to be successful, GenoMed will market it in 2005. GenoMed is currently marketing its protocol for delaying complications, such as kidney failure, of common diseases like high blood pressure and diabetes, which affect 80 million Americans, and emphysema, which affects another 3 million people in the U.S.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment for West Nile virus encephalitis continues to be as effective as it has been so far; (b) whether our server holds up to global demand; (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
--------------------------------------------------------------------------------
Source: GenoMed, Inc. |
